Table 2.
Allele-specific HER2-mutant responses to neratinib using ER+ HER2-mutant breast cancer clinical trials data.
| HER2 mutations | PD | SD | PR | CR |
|---|---|---|---|---|
| L755S/P | 18 | 11 | 3 | 2 |
| L755 alterations | 1 | 1 | 2 | |
| Exon 20 Ins | 1 | 10 | 7 | 3 |
| D769H/Y | 2 | 6 | 1 | 1 |
| L869R | 1 | 4 | ||
| S310F | 5 | 4 | 1 | 2 |
| V8421 | 1 | |||
| V777L | 9 | 2 |
Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
(1) Total number of HER2-mutant breast cancer cases in Hyman et al. (ref. 9; neratinib as a monotherapy), 25 patients (20 ER+ and 5 ER−).
(2) Total number of HER2-mutant breast cancer cases in Smyth et al. (ref. 20; neratinib as a monotherapy), 34 patients (23 ER+ and 11 ER−).
(3) Total number of HER2-mutant breast cancer cases in Ma et al. (ref. 11; neratinib as a monotherapy), 22 patients (21 ER+ and 1 ER−).
(4) Total number of HER2-mutant breast cancer cases in Ma et al. [ref. 28; neratinib alone or neratinib + fulvestrant treated mixed cohort, 40 patients (including neratinib + fulvestrant = 24 patients; neratinib alone = 11 patients; ER+ patients = 35; ER− patients = 5].